The stated goals of the conference were "To discuss and understand the importance of scientific advancements in the paradigm shift toward regenerative medicine, with a particular focus on adult stem cell therapies and the interconnections between research, faith, ethics and culture… [and to] foster an open dialogue amongst researchers, physicians, philanthropists, faith leaders and policy-makers in order to help identify clear, unmet medical needs throughout the world that can be addressed through the development of cellular therapies that will reduce human suffering." The schedule (http://adultstemcellconference.org/the-conference/conference-schedule/) consisted of an array of topics, including presentation of clinical trial results, patients discussing what its like to live with a chronic illness, seminars on the challenges in manufacturing cells for human use, and discussions of the political, ethical, cultural, and societal aspects of stem cell research. The range of clinical topics spanned diabetes mellitus, multiple sclerosis, autoimmune disease, heart disease, traumatic brain injury, aging, wound healing, and cancer. In some cases, patients who had participated in clinical trials were present and discussed their experience.
This was not, strictly speaking, a scientific meeting, although there was a robust presence of scientists, including a Nobel laureate; the mean h-index of the scientists who spoke at the meeting was 54. The meeting, however, was designed to be much broader in scope and included clinicians and scientists working on cell-based therapies, regulators and policy makers, clergy and patients and their families. Unlike a typical scientific session, this meeting attempted to broach some of the societal, cultural, regulatory, and ethical issues raised by stem cell research. It was, therefore, a unique and potentially fertile venue to enable a dialogue among stakeholders that would normally not take place. In lieu of brief question and answer periods after each talk, the meeting program included many breaks and social gatherings designed to provide an opportunity for participants and attendees to interact, engage in discussions, and ask questions. As participants, we can verify that we had many interactions with people with diverse viewpoints whom we would never have met at the meetings we typically attend.
It was sad and disappointing, given the reality of the meeting, that Nature decided to publish an anonymous editorial 1 that was highly misleading, not supported by facts, and essentially an ad hominem attack laced with the type of invective one expects to find in the tabloids, not an esteemed scientific journal.
First, the editorial implied that the meeting was orchestrated to influence the Italian Parliament to deregulate stem cell medicine. This concept seems to have been conjured up by the author(s) of the editorial, as there was nothing at the meeting having anything to do with Italy's Parliament. As noted in the Nature editorial, this was the second Vatican meeting, the first being held nearly 2 years ago. The planning for this meeting began over a year ago, and it was, therefore, fairly clear that there was no connection between the Vatican meeting and anything in the Italian legislature. This manufactured connection between Italian legislature and the Vatican meeting not only discloses the single-minded intention of the author(s) to create the appearance of a conspiracy, but also openly reveals a willingness of the anonymous editorialist(s) to ignore facts. Italy is a member of the European Union. As such, any kind of clinically applied cell therapy is regulated by the European Medicines Agency, which has very clear cut rules for so-called advanced therapeutic medicinal products, which include cell therapy. Italy may, therefore, apply hospital exemption rules in a slightly more liberal fashion, but is nonetheless required to remain adherent to the regulations of the European Union.
Next, in a statement that is highly insulting to the patients who attended the meeting, the editorial claimed that they were paraded before the audience. Apparently, the voices of sick patients and their family members who will be affected by decisions made by researchers, regulators, etc, are not of interest to the author(s) of the editorial, who also seem to assume that these individuals do not exercise free will. By way of contrast, after receiving the Nobel prize in 2012, John Gurdon, one of the conferences speakers, stated "I think patients would be happy to take the risk of using their own cells given the choice." Indeed, the voice of patients has been shown to be very effective in moving therapies forward, the best example being the strong and successful advocacy for the development of treatments for HIV.
In yet another derogatory comment, the author(s) of the editorial state their judgment that the Vatican is scientifically naïve (although it is doubtful that this verdict is based on an analysis of evidence, as would be expected of a scientific journal). Meanwhile, the editorial states that "patients should be exposed to experimental treatments only when
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safety and efficacy is assured." We are just wondering how one would know about safety and efficacy before the experimental treatment has been, well, tested? It is easy to stand on the sidelines, criticizing those who are attempting to help patients by developing novel therapies as scientists desperate to hawk a message that their therapies must be speeded to clinical use. This type of cynicism has been noted repeatedly in the history of medicine. It has been said that one can always identify the pioneers because they are the ones with the arrows in their back.
The Nature editorial speaks of raising false hope of quick fixes; however, the participants at the meeting simply presented data from clinical studies overseen by Food and Drug Administration or European Medicines Agency, just as is done at many other medical meetings. The real question is, why is there a problem with sharing data? It is hard to escape the conclusion that the highly emotional editorial is simply a reaction to the fact that certain biases are being relentlessly overwhelmed by data.
Those biases can also lead to flip-flops of logic. In the current editorial, China is portrayed as a malignant force because of its apparently lax policy toward the use of adult stem cells. However, in a 2010 editorial, the United States was admonished to act more like China when it comes to allowing the use of embryonic stem cells. 2 Meanwhile, the presentation at the Vatican meeting of data from multiple clinical trials involving hundreds if not thousands of patients, conducted by reputable investigators with the approval of appropriate regulatory bodies (Food and Drug Administration and European Medicines Agency), is dismissed as smoke and mirrors. Is this a position that promotes science? Where is the balance, never mind compassion for patients?
We are in a new era of medicine, with many challenges ahead, as well as much hope by and for patients. There is much debate on how to pursue these new therapies. Many have questioned whether any regulatory body should be able to control how patients uses their own cells to treat themselves, as long as manufacturing processes of the cellular product and delivery comply with regulatory rules. In this regard, one wonders if, under the current conditions, autologous bone marrow transplantation could have been developed.
Legitimate questions should be addressed on the basis of data, objective evidence, and rational discussion, and must involve all the stakeholders, including patients.
The trail leading to the use of cell-based therapies to treat diseases is being blazed by a courageous few who would rather try than sit on the sidelines and use distortion and innuendo to criticize. We applaud the Vatican for attempting to shed some light on this subject by inviting a broad array of individuals to discuss the challenges openly and attempt to find solutions.
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